COMMUNIQUÉS West-GlobeNewswire

-
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
28/04/2025 -
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
28/04/2025 -
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
28/04/2025 -
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
28/04/2025 -
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
28/04/2025 -
Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call
28/04/2025 -
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
28/04/2025 -
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
28/04/2025 -
Cronos Group Inc. to Hold Virtual 2025 Annual Meeting of Shareholders
28/04/2025 -
Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025
28/04/2025 -
Supra Keto ACV Gummies: Best Gummies for Weight Loss 2025 - (Keto BHB + Keto Plus)
28/04/2025 -
Best Testosterone Boosters for Muscle Gain: Top Rated Testosterone Pills for Bodybuilding & Muscle Growth From TestoPrime
28/04/2025 -
Sugar Defender Reviews [Blood Sugar Control Supplement 2025] User Complaints, Ingredients and Possible Side Effects?
28/04/2025 -
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
28/04/2025 -
SARMs Cardarine GW 50156: Cardarine For Sale, Cardarine Cycle, Cardarine Benefits, Cardarine Dosage, Cardarine Before and After, Cardarine Effects, Cardarine Side Effects, Buy, (C-Dine By CrazyBulk)
28/04/2025 -
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
28/04/2025 -
IBA – ACQUISITION OF OWN SHARES
28/04/2025 -
IBA – ACQUISITION D’ACTIONS PROPRES
28/04/2025 -
Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF)
28/04/2025
Pages